Evidence map›Paper›PMID 38799461›Full record

ArticleFrontiers in immunology2024

Consolidation therapy with autologous stem cell transplantation after remission of induction chemotherapy prolongs the survival of patients with peripheral T-cell lymphoma.

Wulipan Fulati, Jiexian Ma, Min Wu, Wensi Qian, Pingping Chen, Yingwei Hu, Mingyue Chen, Yu Xu, Zilan Huang, Hongdi Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Wulipan FulatiDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Jiexian MaDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Min WuDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Wensi QianDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Pingping ChenDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Yingwei HuDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Mingyue ChenDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Yu XuDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Zilan HuangDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Hongdi ZhangDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Yanhui XieDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.
Lin ShenDepartment of Hematology, Huadong Hospital Affiliated with Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There was little evidence of autologous stem cell transplantation (ASCT) as consolidation therapy after remission of induction for patients with Peripheral T-cell lymphoma (PTCL). In this study, we conducted a comparative analysis of real-world survival outcomes between consolidation therapy and observation in patients with PTCL. Methods: A total of 92 patients with peripheral T-cell lymphoma (PTCL) who were admitted to the Department of Hematology, Huadong Hospital Affiliated with Fudan University from January 2013 to April 2019 were divided into two groups based on whether they were treated with high-dose therapy (HDT) followed by autologous hematopoietic stem cell transplantation (ASCT): ASCT as consolidation therapy (n=30) and observation (n=62). Clinical characteristics, treatment patterns, and survival outcomes were analyzed between the two groups. Univariate and Cox multivariate regression analyses were also performed to detect prognostic factors of survival. Results: With a median follow-up time of 41 months, the median overall survival (OS) of peripheral T-cell lymphoma patients treated with ASCT was not reached; the median progression-free survival (PFS) was 77.0 months, which was much higher than that of patients without ASCT ( Conclusion: ASCT may improve the long-term survival of patients with PTCL as consolidation therapy after achieving complete or partial remission of induction treatment, particularly for those with high risks. The chemotherapy regimen containing pegylated liposomal doxorubicin may induce deeper remission than traditional doxorubicin in PTCL. It is crucial to identify the specific groups most likely to benefit from upfront ASCT.

Indexed as

Consolidation ChemotherapyHematopoietic Stem Cell TransplantationInduction ChemotherapyLymphoma, T-Cell, PeripheralTransplantation, AutologousAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleHumansMaleMiddle AgedPrognosisRemission InductionRetrospective Studiesautologous hematopoietic stem cell transplantationpegylated liposomal doxorubicinperipheral T cell lymphomaprognosissurvival analysis

Identifiers

PMID38799461
PMCPMC11116632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.